Bicycle Therapeutics (BCYC) vs Yarrow Bioscience (YARW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Yarrow Bioscience (YARW) has outperformed Bicycle Therapeutics (BCYC) over the past year, losing 26.7% versus a loss of 54.1%. Over five years, BCYC leads with a -94.7% price change compared with -98.6% for YARW. Bicycle Therapeutics is the larger company by market cap ($203.3 million vs $196.5 million), about 1.0 times the size.
Bicycle Therapeutics converts more of its revenue into profit, with a net margin of -301.7% versus -4646.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCYC | YARW |
|---|---|---|
| Share price | $2.90 | $12.90 |
| Market cap | $203.27M | $196.53M |
| 1-day change | -4.92% | -9.35% |
| YTD return | -59.04% | -55.52% |
| 1-year return | -54.11% | -26.70% |
| 5-year return | -94.69% | -98.61% |
| EPS (TTM) | $-2.03 | — |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $72.59M | $570.00K |
| Revenue growth (YoY) | +105.77% | +13.77% |
| Net income (latest FY) | $-218.96M | $-26.48M |
| Operating margin | -340.38% | -5219.12% |
| Net margin | -301.66% | -4646.14% |
| 52-week high | $7.83 | $46.95 |
| 52-week low | $2.85 | $12.39 |
| Distance from 52-week high | -62.96% | -72.52% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +216.21% | +310.85% |
| Average volume | 444.72K | 153.34K |
| Shares outstanding | 50.66M | 15.23M |
| Employees | 288 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- YARW has outperformed BCYC by 27.4 percentage points over the past year.
- Bicycle Therapeutics is more profitable, keeping -301.7 cents of every revenue dollar as net income versus -4646.1 cents for Yarrow Bioscience.
- Bicycle Therapeutics grew revenue faster in its latest fiscal year (+105.77% vs +13.77%).
About Bicycle Therapeutics
BCYC stock →Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing.
Health Care · Biotechnology: Pharmaceutical Preparations · 288 employees
About Yarrow Bioscience
YARW stock →Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
BCYC vs YARW FAQ
Which is bigger, Bicycle Therapeutics or Yarrow Bioscience?
Bicycle Therapeutics (BCYC) is larger, with a market capitalization of $203.27M compared with $196.53M for Yarrow Bioscience (YARW).
Which stock has performed better over the past year, BCYC or YARW?
YARW returned -26.70% over the past 12 months, compared with -54.11% for BCYC (price return, excluding dividends). Past performance does not predict future results.
Are Bicycle Therapeutics and Yarrow Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.